Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

BACKGROUND: Transforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib. METHODS: This phase 2 study (NCT01246986) enrolled se...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannelli, Gianluigi, Santoro, Armando, Kelley, Robin K., Gane, Ed, Paradis, Valerie, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Man, Michael, Wang, Shuaicheng, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Faivre, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094874/
https://www.ncbi.nlm.nih.gov/pubmed/32210440
http://dx.doi.org/10.1371/journal.pone.0222259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094874/
https://www.ncbi.nlm.nih.gov/pubmed/32210440
http://dx.doi.org/10.1371/journal.pone.0222259

Ejemplares similares